Brachial Plexopathy Following Use of Recombinant Human BMP-2 for Treatment of Atrophic Delayed Union of the Clavicle

Although recombinant human bone morphogenetic protein-2 (rhBMP-2) is approved for treatment of open tibial fractures and anterior lumbar interbody fusion, off-label use has been associated with complications such as local inflammation, osteolysis, and dysphagia. This case report describes a patient...

Full description

Saved in:
Bibliographic Details
Published inJBJS case connector Vol. 5; no. 3; p. e81
Main Authors Matthews, John R, Margolis, David S, Wu, Eileen, Truchan, Lisa M
Format Journal Article
LanguageEnglish
Published United States 23.09.2015
Online AccessGet more information

Cover

More Information
Summary:Although recombinant human bone morphogenetic protein-2 (rhBMP-2) is approved for treatment of open tibial fractures and anterior lumbar interbody fusion, off-label use has been associated with complications such as local inflammation, osteolysis, and dysphagia. This case report describes a patient treated with rhBMP-2 for an atrophic delayed union of a clavicular fracture who subsequently developed a profound motor and sensory brachial plexopathy. Use of rhBMP-2 near peripheral nerves may cause neuropathy. This should be considered prior to its use in surgical sites with peripheral nerves in proximity.
ISSN:2160-3251
DOI:10.2106/JBJS.CC.N.00187